Dysglycaemia in the critically ill - significance and management

Diabetes, Obesity and Metabolism

Volumn 15, Issue 9, 2013, Pages 792-801

  Deane, A M ^a,b   Horowitz, M ^a,c  

^a Department of Neurosurgery   (South Africa)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Critical illness; GLP 1; GLP 1 analogue; Incretins

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INSULIN; LINAGLIPTIN; SHORT ACTING INSULIN;

CRITICALLY ILL PATIENT; DIABETES MELLITUS; DYSGLYCEMIA; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLUCAGONEMIA; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN RESISTANCE; INSULIN TREATMENT; PATHOGENESIS; PREVALENCE; REVIEW; SEPSIS;

CRITICAL ILLNESS; GLP-1; GLP-1 ANALOGUE; INCRETINS;

ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CRITICAL ILLNESS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; RISK FACTORS;

EID: 84880811313     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12078     Document Type: Review

References (67)

1. Bernard C. Lecons sur le Diabete et la Glycogenase et la Animale. Paris: Bailliere, 1877.
2. Kavanagh BP, McCowen KC. Clinical practice glycemic control in the ICU. N Engl J Med 2011; 363: 2540-2546.
3. Clement S, Braithwaite SS, Magee MF et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004; 27: 553-591.
4. Finfer S, Chittock DR, Su SY et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-1297.
5. Stegenga ME, Vincent JL, Vail GM et al. Diabetes does not alter mortality or hemostatic and inflammatory responses in patients with severe sepsis. Crit Care Med 2010; 38: 539-545.
6. Egi M, Bellomo R, Stachowski E et al. Blood glucose concentration and outcome of critical illness: the impact of diabetes. Crit Care Med 2008; 36: 2249-2255.
7. Van Den Berghe G, Wilmer A, Hermans G et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354: 449-461.
8. Preiser JC, Devos P, Ruiz-Santana S et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the glucontrol study. Intensive Care Med 2009; 35: 1738-1748.
9. Gornik I, Vujaklija-Brajkovic A, Renar IP, Gasparovic V. A prospective observational study of the relationship of critical illness associated hyperglycaemia in medical ICU patients and subsequent development of type 2 diabetes. Crit Care 2010; 14: R130.
10. Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet 2009; 373: 1798-1807.
11. Egi M, Bellomo R, Stachowski E et al. The interaction of chronic and acute glycemia with mortality in critically ill patients with diabetes. Crit Care Med 2011; 39: 105-111.
12. Nathan DM. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32: 1327-1334.
13. Cely CM, Arora P, Quartin AA, Kett DH, Schein RM. Relationship of baseline glucose homeostasis to hyperglycemia during medical critical illness. Chest 2004; 126: 879-887.
14. Soulimane S, Simon D, Shaw J et al. HbA1c, fasting plasma glucose and the prediction of diabetes: Inter99, AusDiab and D.E.S.I.R. Diabetes Res Clin Pract 2012; 96: 392-399.
15. Van Den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359-1367.
16. Finfer S, Liu B, Chittock DR et al. Hypoglycemia and risk of death in critically ill patients. N Engl J Med 2012; 367: 1108-1118.
17. Bagshaw SM, Bellomo R, Jacka MJ, Egi M, Hart GK, George C. The impact of early hypoglycemia and blood glucose variability on outcome in critical illness. Crit Care 2009; 13: R91.
18. Krinsley JS, Grover A. Severe hypoglycemia in critically ill patients: risk factors and outcomes. Crit Care Med 2007; 35: 2262-2267.
19. Brunkhorst FM, Engel C, Bloos F et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125-139.
20. Krinsley JS. Glycemic variability in critical illness and the end of chapter 1. Crit Care Med 2010; 38: 1206-1208.
21. Egi M, Bellomo R, Stachowski E, French CJ, Hart G. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 2006; 105: 244-252.
22. Ali NA, O'Brien JM Jr, Dungan K et al. Glucose variability and mortality in patients with sepsis. Crit Care Med 2008; 36: 2316-2321.
23. Krinsley JS. Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med 2008; 36: 3008-3013.
24. Meyfroidt G, Keenan DM, Wang X, Wouters PJ, Veldhuis JD, Van Den Berghe G. Dynamic characteristics of blood glucose time series during the course of critical illness: effects of intensive insulin therapy and relative association with mortality. Crit Care Med 2010; 38: 1021-1029.
25. Lundelin K, Vigil L, Bua S, Gomez-Mestre I, Honrubia T, Varela M. Differences in complexity of glycemic profile in survivors and nonsurvivors in an intensive care unit: a pilot study. Crit Care Med 2010; 38: 849-854.
26. Mackenzie IM, Whitehouse T, Nightingale PG. The metrics of glycaemic control in critical care. Intensive Care Med 2011; 37: 435-443.
27. Brunner R, Adelsmayr G, Herkner H, Madl C, Holzinger U. Glycemic variability and glucose complexity in critically ill patients: a retrospective analysis of continuous glucose monitoring data. Crit Care 2012; 16: R175.
28. Mizock BA. Alterations in fuel metabolism in critical illness: hyperglycaemia. Best Pract Res Clin Endocrinol Metab 2001; 15: 533-551.
29. Mehta VK, Hao W, Brooks-Worrell BM, Palmer JP. Low-dose interleukin 1 and tumor necrosis factor individually stimulate insulin release but in combination cause suppression. European Journal of Endocrinology/European Federation of Endocrine Societies 1994; 130: 208-214.
30. Jahoor F, Herndon DN, Wolfe RR. Role of insulin and glucagon in the response of glucose and alanine kinetics in burn-injured patients. J Clin Invest 1986; 78: 807-814.
31. Krinsley JS, Meyfroidt G, Van Den Berghe G, Egi M, Bellomo R. The impact of premorbid diabetic status on the relationship between the three domains of glycemic control and mortality in critically ill patients. Curr Opin Clin Nutr Metab Care 2012; 15: 151-160.
32. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829.
33. Casaer MP, Mesotten D, Hermans G et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med 2011; 365: 506-517.
34. Marik PE, Preiser JC. Toward understanding tight glycemic control in the ICU: a systematic review and metaanalysis. Chest 2010; 137: 544-551.
35. Ichai C, Preiser JC. International recommendations for glucose control in adult non diabetic critically ill patients. Crit Care 2010; 14: R166.
36. Vincent JL, Preiser JC, Sprung CL, Moreno R, Sakr Y. Insulin-treated diabetes is not associated with increased mortality in critically ill patients. Crit Care 2010; 14: R12.
37. Graham BB, Keniston A, Gajic O, Trillo Alvarez CA, Medvedev S, Douglas IS. Diabetes mellitus does not adversely affect outcomes from a critical illness. Crit Care Med 2010; 38: 16-24.
38. Van Den Berghe G, Wilmer A, Milants I et al. Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm. Diabetes 2006; 55: 3151-3159.
39. Rady MY, Johnson DJ, Patel BM, Larson JS, Helmers RA. Influence of individual characteristics on outcome of glycemic control in intensive care unit patients with or without diabetes mellitus. Mayo Clin Proc 2005; 80: 1558-1567.
40. Krinsley JS. Glycemic control, diabetic status, and mortality in a heterogeneous population of critically ill patients before and during the era of intensive glycemic management: six and one-half years experience at a university-affiliated community hospital. Semin Thorac Cardiovasc Surg 2006; 18: 317-325.
41. Falciglia M, Freyberg RW, Almenoff PL, D'Alessio DA, Render ML. Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. Crit Care Med 2009; 37: 3001-3009.
42. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
43. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
44. Egi M, Bellomo R, Stachowski E et al. Hypoglycemia and outcome in critically ill patients. Mayo Clin Proc 2010; 85: 217-224.
45. Duning T, Van Den Heuvel I, Dickmann A et al. Hypoglycemia aggravates critical illness-induced neurocognitive dysfunction. Diabetes Care 2010; 33: 639-644.
46. Mesotten D, Gielen M, Sterken C et al. Neurocognitive development of children 4 years after critical illness and treatment with tight glucose control: a randomized controlled trial. JAMA 2012; 308: 1641-1650.
47. Dossett LA, Cao H, Mowery NT, Dortch MJ, Morris JM Jr, May AK. Blood glucose variability is associated with mortality in the surgical intensive care unit. Am Surg 2008; 74: 679-685.
48. Krinsley JS. Glycemic variability and mortality in critically ill patients: the impact of diabetes. J Diabetes Sci Technol 2009; 3: 1292-1301.
49. Chase JG, Shaw G, Le Compte A et al. Implementation and evaluation of the SPRINT protocol for tight glycaemic control in critically ill patients: a clinical practice change. Crit Care 2008; 12: R49.
50. Van Herpe T, De Moor B, Van Den Berghe G. Towards closed-loop glycaemic control. Best Pract Res Clin Anaesthesiol 2009; 23: 69-80.
51. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-307.
52. Deacon CF. What do we know about the secretion and degradation of incretin hormones? Regul Pept 2005; 128: 117-124.
53. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
54. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830.
55. Combes J, Borot S, Mougel F, Penfornis A. The potential role of glucagon-like peptide-1 or its analogues in enhancing glycaemic control in critically ill adult patients. Diabetes Obes Metab 2011; 13: 118-129.
56. Deane AM, Chapman MJ, Fraser RJ, Burgstad CM, Besanko LK, Horowitz M. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Crit Care 2009; 13: R67.
57. Deane AM, Chapman MJ, Fraser RJ et al. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. Crit Care Med 2010; 38: 1261-1269.
58. Deane AM, Summers MJ, Zaknic AV et al. Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes. Crit Care 2011; 15: R35.
59. Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3853-3860.
60. Deane AM, Chapman MJ, Horowitz M. The therapeutic potential of a venomous lizard: the use of glucagon-like peptide-1 analogues in the critically ill. Crit Care 2010; 14: 1004.
61. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B. Gastric inhibitory polypeptide: the neglected incretin revisited. Regul Pept 2002; 107(1-3): 1-13.
62. Hojberg PV, Vilsboll T, Rabol R et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009; 52: 199-207.
63. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76: 912-917.
64. Elahi D, McAloon-Dyke M, Fukagawa NK et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 1994; 51: 63-74.
65. Mentis N, Vardarli I, Kothe LD et al. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes 2011; 60: 1270-1276.
66. Deacon CF, Mannucci E, Ahren B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes Obes Metab 2012; 14: 762-767.
67. Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939-946.